intralesional

Type: Keyphrase
Name: intralesional
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Liposomal amphotericin B reduces duration of L. tropica in children

Systemic therapy with liposomal amphotericin B resulted in a considerably shorter duration of Leishmania tropica in children than treatment with pentavalent antimony, according to study findings.In the retrospective study, 47 children with L . tropica ... [Published Orthopedics Today - 8 hours ago]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

The Product Development Story Of Provectus Biopharmaceuticals

Summary Provectus Biopharmaceuticals is developing a product with a very compelling story. Its premier product is PV-10, used in cancerous tumors, notably melanoma. PV-10 destroys tumors by homing in on their acidic environment and exploding the cancerous ... [Published Seeking Alpha - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Xerese for the Treatment of Herpes Labialis

Harrison P. Nguyen, BA, Kelly R. Stiegel, BS, Christopher Downing, MD, Stephen K. Tyring, MD, PhD, MBADisclosuresSkin Therapy Letter. 2014;19(3)Abstract and Introduction AbstractHerpes labialis is a frequently occurring viral infection of the lips ... [Published General Medicine eJournal - Jul 25 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Primary Spine Tumors: Diagnosis and Treatment

Boriani S, Biagini R, De Iure FD, et al. Primary bone tumors of the spine: a survey of the evaluation and treatment at the Instituto Ortopedico Rizzoli. Orthopedics. 1995;18(10):993–1000.Jacobs W, Fehlings M. Primary vertebral column tumors. In: Dickman ... [Published General Medicine eJournal - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

OncoSec Medical To Present at 2014 DNA Vaccine Conference

Leading the Discussion in Tumor Targeted ImmunotherapySAN DIEGO--(BUSINESS WIRE)--July 17, 2014--OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives ... [Published Scottrade - Jul 17 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Necrobiosis Lipoidica (Diabeticorum)

Click to enlarge. Click to enlarge.Over several years, brown plaques developed on the legs a 59-year-old woman with diabetes mellitus and pulmonary sarcoidosis. The plaques were dry and cracked in the winter but otherwise asymptomatic. Physical examination ... [Published Consultant Live - Jul 15 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Provectus Updates Shareholders in Its Annual CEO -2-

The current phase 1 study, initially designed solely to establish safety of percutaneous injection of PV-10 into liver tumors (that is, injection through the skin), is providing valuable data crucial for planning such phase 2 development. This trial is ... [Published Scottrade - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Somerton man with incurable condition forces change to national...

Comments (0)A SOMERTON man who has suffered an excruciating spinal condition for 20 years has been congratulated by MP David Blunkett for sparking national change to UK drugs guidelines.International drugs giant Pfizer has this week agreed to change its ... [Published Western Gazette - Jul 07 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Provectus: Strong Sell On Unviable Phase III Trial, Insufficient Cash, And Fraud Allegations

Summary Additional research indicates PVCT’s Phase 3 Trial is designed in such a way that it seems completely unviable and effectively impossible to enroll or execute. Both industry data and PVCT’s own internally generated documents show the current ... [Published Seeking Alpha - Jun 24 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Insect bite to blame for itchy nodule

This solitary nodule developed on a woman’s cheek over five weeks.IT WAS slightly itchy but did not bleed. On prompting she thought she might have had an insect bite.Purple red nodules like this are suggestive of a lymphocytoma, a localised collection ... [Published Medical Observer - Jun 24 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin

The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions ... [Published PharmCast - Mar 19 2014]

Quotes

The current state of knowledge was summed up by Dr. Jeffrey Weber, the senior author of the presentation by the Moffitt Cancer Center: "This data provides more and more evidence that you are altering both local and systemic immunity in a positive way. It also provides a rationale for combination trials of PV-10 with check point protein inhibitors, such as ipilimumab, pembrolizumab and nivolumab."
Punit Dhillon, President and CEO, announced, "We are proud to be a Chairman's Cup Sponsor for this event. Each year, ISDV's annual DNA Vaccines conference has become larger and better attended by key thought leaders in the space, and this year is no different. Including OncoSec, several of the leading companies in developing electroporation technology for DNA vaccines and immunotherapy will be presenting and sharing data, and this year, OncoSec will lead the discussion in the importance of developing intratumoral immunotherapies using electroporation."
"Ensuring the safety of patients is of paramount importance to Pfizer. We have a rigorous system to ensure our medicines are safe and efficacious, and suitable for patient use. We work closely with the MHRA to review and evaluate the risks and benefits of a medicine before and after the medicine is available to patients, and to communicate this information to healthcare providers and patients. The benefit risk profile of Depo-Medrone is supported by extensive clinical and post-marketing experience. Patients who are prescribed Depo-Medrone should speak with their healthcare professional if they have questions or concerns regarding their treatment."
...allegedly in a "implemented and directed a scheme to manipulate the price of a stock."

More Content

All (11) | News (11) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Liposomal amphotericin B reduces duration of L.... [Published Orthopedics Today - 8 hours ago]
The Product Development Story Of Provectus Biop... [Published Seeking Alpha - Jul 28 2014]
Xerese for the Treatment of Herpes Labialis [Published General Medicine eJournal - Jul 25 2014]
Primary Spine Tumors: Diagnosis and Treatment [Published General Medicine eJournal - Jul 18 2014]
OncoSec Medical To Present at 2014 DNA Vaccine ... [Published Scottrade - Jul 17 2014]
Necrobiosis Lipoidica (Diabeticorum) [Published Consultant Live - Jul 15 2014]
Provectus Updates Shareholders in Its Annual CE... [Published Scottrade - Jul 08 2014]
Somerton man with incurable condition forces ch... [Published Western Gazette - Jul 07 2014]
Provectus: Strong Sell On Unviable Phase III Tr... [Published Seeking Alpha - Jun 24 2014]
Insect bite to blame for itchy nodule [Published Medical Observer - Jun 24 2014]
Treatment of hepatitis C virus with telaprevir ... [Published PharmCast - Mar 19 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.